Intravenous Liposomal Amphotericin as an Adjunct to Fluconazole in Pediatric Patients With Central Nervous System Coccidioidomycosis: A Single-Center Case Series
Related Experiment Video
Updated: Jan 11, 2026

Live Imaging of Antifungal Activity by Human Primary Neutrophils and Monocytes in Response to A. fumigatus
Published on: April 19, 2017
Kajal Maran1, Ruzan Adams2, Aslam Khan2
1Department of Neurology and Neurological Sciences, Division of Child Neurology, Stanford University, Palo Alto, CA, United States.
Background:
Coccidioidomycosis is a fungal infection endemic to the southwestern United States. Central nervous system (CNS) coccidioidomycosis is a severe manifestation that requires lifelong antifungal therapy. While fluconazole is currently recommended as the initial therapy in pediatric patients, a rise in reports of fluconazole failure has led to use of alternative treatment approaches. In this paper, we evaluated our institutional preference to use intravenous (IV) liposomal amphotericin B (L-AmB) as part of the initial therapy for pediatric CNS coccidioidomycosis.
Methods:
We conducted a retrospective case series of pediatric patients diagnosed with CNS coccidioidomycosis between 2010 and 2024. Clinical presentation, diagnostics, treatment strategies, and outcomes were analyzed.
Results:
Among 10 patients, 6 had mild initial symptoms of fevers and/or headaches, while 4 had more severe initial presentations, including focal deficits, seizures, or altered mental status. All severe cases received immediate IV L-AmB and fluconazole (+IV L-AmB); 75% were discharged with improvement. The 2 mild cases that received early +IV L-AmB had uncomplicated courses, while 2 of the 4 mild cases initially treated with fluconazole alone progressed to severe disease. Over an average follow-up of 4.5 years, 5 patients were fully functional without neurologic deficits, 2 had mild residual deficits, and 3 died. Relapse occurred in all but 1 patient. Patients receiving early +IV L-AmB trended toward shorter hospitalizations, lower disease progression rates, and delayed disease relapse.
Conclusions:
Our institutional experience with IV L-AmB in combination with fluconazole for the initial management of pediatric CNS coccidioidomycosis suggests that +IV L-AmB may help reduce disease progression and improve symptom resolution with mild and transient side effects, although the findings of this case series should be interpreted cautiously due to the small cohort size, limited generalizability, and potential confounding factors.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution

